¼¼°è ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - Á¡À¯À², ½ÃÀå ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼ : ¾àÁ¦º°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº° ºÎ¹® ¿¹Ãø(2024-2032³â)
Cytomegalovirus Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug (Ganciclovir, Valganciclovir, Cidofovir, Foscarnet, Others); By Application; By Distribution Channel; By Region; Segment Forecast, 2024- 2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Polaris Market ResearchÀÇ ÃÖ±Ù Á¶»ç¿¡ µû¸£¸é, ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ¼¼°è ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 10¾ï 3,516¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ ¼³¹®Á¶»ç º¸°í¼´Â ÇöÀç ½ÃÀå ¿ªÇÐÀ» ÀÚ¼¼È÷ ÆÄ¾ÇÇϰí ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
Çõ½ÅÀûÀÎ Ä¡·á Á¢±Ù¹ýÀº ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º(CMV) Ä¡·á ½ÃÀåÀÇ °·ÂÇÑ ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù. Ç×¹ÙÀÌ·¯½ºÁ¦¹° °³¹ß, ¸é¿ª¿ä¹ý ¹× Ç¥Àû Ä¡·á¿¡ ´ëÇÑ »õ·Î¿î Àü·«À¸·Î ½ÃÀåÀÌ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÔ¾ç T ¼¼Æ÷ ÀÌ½Ä ¹× ¸é¿ªÁ¶ÀýÁ¦´Â CMV °¨¿°¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀ» Áõ°¡½Ãų ¼ö ÀÖ´Â °ÍÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù. ÷´Ü ¾à¹° Á¦Á¦¿Í º´¿ë ¿ä¹ý¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ Á¶»ç¸¦ ÅëÇØ ´õ¿í È¿°úÀûÀ̰í Ç¥ÀûÈµÈ ¿É¼ÇÀÌ Åº»ýÇϰí ÀÖ½À´Ï´Ù. CMV Ä¡·á ½ÃÀåÀº ¼±ÁøÀûÀ̰í ȯÀÚ Á᫐ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¿¡ ÀûÀÀÇϰí ÀÖÀ¸¸ç, ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º °¨¿°°ú °ü·ÃµÈ º¹ÀâÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ °úÇÐÀû Áøº¸¿Í Ä¡·á Çõ½ÅÀÇ ½Ã³ÊÁö È¿°ú¸¦ º¸¿©ÁÝ´Ï´Ù.
CMV °¨¿°ÀÌ °øÁß º¸°Ç¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÀνÄÇϰí, °¢±¹ Á¤ºÎ´Â ¿¬±¸, Áø´Ü ¹× °í±Þ Ä¡·á ¼Ö·ç¼Ç¿¡ Àû±ØÀûÀ¸·Î ÀÚ±ÝÀ» ÇÒ´çÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àü·«Àû ³ë·ÂÀº ÀÎÁöµµ Çâ»ó, Á¶±â ¹ß°ß È®º¸, ÃÖ÷´Ü Ä¡·á Á¢±ÙÀ» ÃËÁøÇÏ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù. ƯÈ÷ °£½ÃŬ·Îºñ¸£¿Í °°Àº Ç×¹ÙÀÌ·¯½ºÁ¦ÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÀçÁ¤Áö¿øÀº CMV Ä¡·áÀÇ ¼öÁØÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤ºÎ ÁÖµµ ÇÁ·Î±×·¥Àº »çȸÀû ¾àÀÚÀÇ Æ¯Á¤ °úÁ¦¸¦ ´ë»óÀ¸·Î Çϸç CMV Ä¡·áÀÇ Çù·ÂÀûÀÎ Áøº¸¸¦ ÃËÁøÇÏ°í º¸´Ù ±¤¹üÀ§ÇÑ ¼¼°è °øÁß º¸°Ç ¸ñÇ¥¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
ÇÙ»ê ÁõÆø ºÐ¼® ¹× Ç÷ûÇÐÀû °Ë»ç¿Í °°Àº Á¤¹ÐÇÏ°í ½Å¼ÓÇÑ µµ±¸´Â Á¶±â ¹× Á¤È®ÇÑ CMV °ËÃâÀ» °¡´ÉÇÏ°Ô Çϸç, °£½ÃŬ·Îºñ¸£¿Í °°Àº Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù. Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç¿Í °í±Þ ¿µ»ó Áø´Ü¹ýÀº Áø´Ü ´É·ÂÀ» ´õ¿í Çâ»ó½ÃŰ°í ½Ã±â ÀûÀýÇÑ CMV ½Äº°À» À§ÇÑ »õ·Î¿î ±æÀ» ¿¾îÁÝ´Ï´Ù. ÷´Ü Áø´Ü ¹× Ä¡·á¹ýÀÇ ½Ã³ÊÁö È¿°ú·Î ȯÀÚ °ü¸®¸¦ À籸¼ºÇÏ°í ¸ÂÃã Ä¡·á Á¢±Ù¹ýÀ» Á¦°øÇÕ´Ï´Ù. ±â¼ú ÁøÈ°¡ ÁøÇàµÊ¿¡ µû¶ó CMV Ä¡·á ½ÃÀåÀº ¼ºÀå ±âȸ°¡ È®´ëµÇ°í ȯÀÚÀÇ °á°ú¸¦ Çâ»ó½ÃŰ´Â µ¥ Çõ½ÅÀÌ Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù.
°³ÀÎÈµÈ °Ç° °ü¸®·ÎÀÇ ÀüȯÀº Ä¡·á °èȹÀ» °³º° ¿ä±¸¿¡ ¸Â°Ô Á¶Á¤Çϰí, ¾îµåÈ÷¾î·±½º¸¦ ³ôÀ̰í, CMV °¨¿°ÀÇ º¹À⼺À» ÇØ°áÇÕ´Ï´Ù. Çõ½ÅÀûÀÎ Ä¡·á¹ýÀº ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈÇϰí Ä¡·á ¼ºÀûÀ» °³¼±ÇÏ´Â °ÍÀ» ÃÖ¿ì¼±À¸·Î Çϰí, ȯÀÚ Ä£ÈÀûÀÎ Åõ¿©¹ý°ú º´¿ë ¿ä¹ýÀº CMV Ä¡·áÀÇ ÁøÈ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ȯÀÚ Áß½ÉÀÇ ÀÇ·á µ¿Çâ°ú ÇÔ²²ÀÌ ½ÃÀåÀº ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º °¨¿° Ä¡·áÀÇ Áøº¸¿Í ÃÖÀûȸ¦ À§ÇØ À¯¸ÁÇÕ´Ï´Ù.
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
2023³â¿¡´Â Ç×¹ÙÀÌ·¯½º È¿°ú, ¹ÙÀÌ·¯½ºÀÇ ¼±ÅÃÀû Ç¥ÀûÈ, ÀÓ»óÀû È¿´ÉÀ¸·Î °£½ÃŬ·Îºñ¸£ ºÎ¹®ÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
2023³â¿¡´Â CMV ÀçȰ¼ºÈ À§Çè Áõ°¡¿Í Àü¹ÝÀûÀÎ °á°ú °³¼±ÀÇ Çʿ伺À¸·Î Áٱ⼼Æ÷ ÀÌ½Ä ºÐ¾ß°¡ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
2023³â, º´¿ø ¾à±¹ ºÎ¹®Àº ȯÀÚÀÇ Áö¼ÓÀûÀÎ Áø´Ü ¹× ¸ð´ÏÅ͸µ, °Ç° °ü¸® À¯´Ö ³» Á¢±Ù¼ºÀÇ ¿ëÀ̼ºÀ¸·Î ÀÎÇØ Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
2023³â¿¡´Â ºÏ¹Ì°¡ CMV °¨¿°ÀÇ À¯Çà°ú ¹ß»ý·ü, ¿¬±¸°³¹ß¿¡ ÀÇÇØ ¼¼°è ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
Á¦4Àå ¼¼°èÀÇ ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå ÀλçÀÌÆ®
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - À¯Åë ä³ÎÀÇ ½º³À¼¦
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀΰú ±âȸ
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º °¨¿°ÀÇ ¹ß»ý·ü Áõ°¡·Î Á¦Ç° ¼ö¿ä°¡ ÀÚ±ØµÉ °ÍÀ¸·Î ¿¹Ãø
ÀÌ½Ä È°µ¿ Áõ°¡¿¡ ÀÇÇØ ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀÌ ±â´ëµÊ
¾ïÁ¦¿äÀΰú °úÁ¦
°í¾×ÀÇ Ä¡·áºñ°¡ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ °¡´É¼ºÀÌ ÀÖ´Ù
PESTEL ºÐ¼®
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå À¯Åë ä³ÎÀÇ µ¿Çâ
¹ë·ùüÀÎ ºÐ¼®
COVID-19 °¨¿°ÀÇ ¿µÇ⠺м®
Á¦5Àå ¼¼°èÀÇ ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¾àÁ¦º°
ÁÖ¿ä Á¶»ç °á°ú
¼Ò°³
°£»çÀÌŬ·Îºñ¾î
¹ß°£»çÀÌŬ·Îºñ¾î
½ÃµåÆ÷ºñ¸£
Æ÷½ºÄ«³Ý
±âŸ
Á¦6Àå ¼¼°èÀÇ ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¿ëµµº°
ÁÖ¿ä Á¶»ç °á°ú
¼Ò°³
Àå±â À̽Ä
Áٱ⼼Æ÷ À̽Ä
¼±Ãµ¼º CMV °¨¿°Áõ
±âŸ
Á¦7Àå ¼¼°èÀÇ ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, À¯Åë ä³Îº°
ÁÖ¿ä Á¶»ç °á°ú
¼Ò°³
º´¿ø ¾à±¹
¼Ò¸Å ¾à±¹
±âŸ
Á¦8Àå ¼¼°èÀÇ ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, Áö¿ªº°
ÁÖ¿ä Á¶»ç °á°ú
¼Ò°³
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå Æò°¡, Áö¿ªº°(2019-2032³â)
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ºÏ¹Ì
ºÏ¹Ì : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¾àÁ¦º°(2019-2032³â)
ºÏ¹Ì : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, À¯Åë ä³Îº°(2019-2032³â)
ºÏ¹Ì : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¿ëµµº°(2019-2032³â)
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ¹Ì±¹
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ij³ª´Ù
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - À¯·´
À¯·´ : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¾àÁ¦º°(2019-2032³â)
À¯·´ : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, À¯Åë ä³Îº°(2019-2032³â)
À¯·´ : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¿ëµµº°(2019-2032³â)
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ¿µ±¹
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ÇÁ¶û½º
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - µ¶ÀÏ
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ÀÌÅ»¸®¾Æ
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ½ºÆäÀÎ
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ³×´ú¶õµå
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ·¯½Ã¾Æ
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ¾Æ½Ã¾ÆÅÂÆò¾ç
¾Æ½Ã¾ÆÅÂÆò¾ç : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¾àÁ¦º°(2019-2032³â)
¾Æ½Ã¾ÆÅÂÆò¾ç : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, À¯Åë ä³Îº°(2019-2032³â)
¾Æ½Ã¾ÆÅÂÆò¾ç : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¿ëµµº°(2019-2032³â)
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - Áß±¹
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - Àεµ
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ¸»·¹À̽þÆ
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ÀϺ»
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - Àεµ³×½Ã¾Æ
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - Çѱ¹
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¾àÁ¦º°(2019-2032³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, À¯Åë ä³Îº°(2019-2032³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¿ëµµº°(2019-2032³â)
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - »ç¿ìµð¾Æ¶óºñ¾Æ
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - À̽º¶ó¿¤
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ³²¾ÆÇÁ¸®Ä«
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ¶óƾ¾Æ¸Þ¸®Ä«
¶óƾ¾Æ¸Þ¸®Ä« : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¾àÁ¦º°(2019-2032³â)
¶óƾ¾Æ¸Þ¸®Ä« : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, À¯Åë ä³Îº°(2019-2032³â)
¶óƾ¾Æ¸Þ¸®Ä« : ½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå, ¿ëµµº°(2019-2032³â)
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ¸ß½ÃÄÚ
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ºê¶óÁú
½ÃÅä¸Þ°¥·Î¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ¾Æ¸£ÇîÆ¼³ª
Á¦9Àå °æÀï ±¸µµ
È®Àå ¹× Àμö ºÐ¼®
Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³
Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ
Bayer AG
Bristol Myers Squibb
Chimerix
Clinigen Group
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Fresenius Kabi
Genentech, Inc.
Gilead Sciences, Inc
GlaxoSmithKline plc
Merck & Co., Inc.
Pfizer Inc
Takeda Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
JHS
The global Cytomegalovirus Treatment market size is expected to reach USD 1,035.16 million by 2032, according to a new study by Polaris Market Research. The report "Cytomegalovirus Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug (Ganciclovir, Valganciclovir, Cidofovir, Foscarnet, Others); By Application; By Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Innovative therapeutic approaches are propelling robust growth in the Cytomegalovirus (CMV) Treatment Market. The market is transforming with novel strategies in antiviral drug development, immunotherapies, and targeted treatments. Adoptive T-cell transfer and immune modulators are gaining recognition for their potential to boost immune responses against CMV infections. Ongoing research into advanced drug formulations and combination therapies is generating more effective and targeted options. The CMV treatment market is adapting to the demand for advanced and patient-centric solutions, showcasing the synergy between scientific advancements and therapeutic innovation in addressing complexities associated with cytomegalovirus infections.
Recognizing the public health impact of CMV infections, governments globally are actively allocating funds for research, diagnosis, and advanced treatment solutions. These strategic efforts focus on increasing awareness, ensuring early detection, and promoting accessibility to cutting-edge therapies. Financial support for research and development, particularly in antiviral drugs like Ganciclovir, elevates the standard of CMV treatment. Government-led programs also target specific challenges in vulnerable populations, fostering collaborative advancements in the CMV treatment landscape and contributing to broader global public health goals.
Precise and rapid tools like nucleic acid amplification assays and serological tests enable early and accurate CMV detection, driving demand for treatments such as Ganciclovir. Point-of-care testing and sophisticated imaging modalities further enhance diagnostic capabilities, opening new avenues for timely CMV identification. The synergy between advanced diagnostics and treatment modalities reshapes patient care, offering personalized therapeutic approaches. With ongoing technological evolution, the CMV treatment market is set to witness expanded growth opportunities, emphasizing the central role of innovation in enhancing overall patient outcomes.
The shift towards personalized healthcare tailors treatment plans to individual needs, enhancing adherence and addressing CMV infection complexities. Innovative therapies prioritize minimizing side effects and improving outcomes, while patient-friendly administration methods and combination therapies contribute to the evolving CMV treatment landscape. Aligned with the trend of patient-centric care, the market holds promise for advancing and optimizing treatments for cytomegalovirus infections.
Cytomegalovirus Treatment Market Report Highlights
In 2023, the ganciclovir segment accounted for significant market share owing to antiviral efficacy, selective viral targeting, and clinical effectiveness.
In 2023, the stem cell transplantation segment accounted for significant market share owing to elevated risk of CMV reactivation and need for improving overall outcomes.
In 2023, the hospital pharmacy segment held significant revenue share owing to continuous diagnosis and monitoring of patients, and ease of access within healthcare units.
In 2023, North America region dominated the global market due to prevalence and incidence of CMV infections, and research and development.
The market is highly competitive owing to the existence of market players with a global presence, including Clinigen Group, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Gilead Sciences, Inc., Takeda Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. among others.
Polaris Market Research has segmented the Cytomegalovirus Treatment market report based on drug, application, distribution channel, and region:
Cytomegalovirus Treatment, Drug Outlook (Revenue - USD Million, 2019 - 2032)
Ganciclovir
Valganciclovir
Cidofovir
Foscarnet
Others
Cytomegalovirus Treatment, Application Outlook (Revenue - USD Million, 2019 - 2032)
Organ Transplantation
Stem Cell Transplantation
Congenital CMV Infection
Others
Cytomegalovirus Treatment, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)
Hospital Pharmacy
Retail Pharmacy
Others
Cytomegalovirus Treatment, Regional Outlook (Revenue - USD Million, 2019 - 2032)
North America
U.S.
Canada
Europe
France
Germany
UK
Italy
Netherlands
Spain
Russia
Asia Pacific
Japan
China
India
Malaysia
Indonesia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Table of Contents
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
3. Research Methodology
3.1. Overview
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Cytomegalovirus Treatment Market Insights
4.1. Cytomegalovirus Treatment Market - Distribution Channel Snapshot
4.2. Cytomegalovirus Treatment Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Increasing incidence of cytomegalovirus infections is projected to spur the product demand
4.2.1.2. Rising transplantation activities is expected to drive cytomegalovirus treatment market growth
4.2.2. Restraints and Challenges
4.2.2.1. High cost of treatment is likely to impede the market growth
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Cytomegalovirus Treatment Market Distribution Channel Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Cytomegalovirus Treatment Market, by Drug
5.1. Key Findings
5.2. Introduction
5.2.1. Global Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
5.3. Ganciclovir
5.3.1. Global Cytomegalovirus Treatment Market, by Ganciclovir, by Region, 2019-2032 (USD Million)
5.4. Valganciclovir
5.4.1. Global Cytomegalovirus Treatment Market, by Valganciclovir, by Region, 2019-2032 (USD Million)
5.5. Cidofovir
5.5.1. Global Cytomegalovirus Treatment Market, by Cidofovir, by Region, 2019-2032 (USD Million)
5.6. Foscarnet
5.6.1. Global Cytomegalovirus Treatment Market, by Foscarnet, by Region, 2019-2032 (USD Million)
5.7. Others
5.7.1. Global Cytomegalovirus Treatment Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Cytomegalovirus Treatment Market, by Application
6.1. Key Findings
6.2. Introduction
6.2.1. Global Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
6.3. Organ Transplantation
6.3.1. Global Cytomegalovirus Treatment Market, by Organ Transplantation, by Region, 2019-2032 (USD Million)
6.4. Stem Cell Transplantation
6.4.1. Global Cytomegalovirus Treatment Market, by Stem Cell Transplantation, by Region, 2019-2032 (USD Million)
6.5. Congenital CMV Infection
6.5.1. Global Cytomegalovirus Treatment Market, by Congenital CMV Infection, by Region, 2019-2032 (USD Million)
6.6. Others
6.6.1. Global Cytomegalovirus Treatment Market, by Others, by Region, 2019-2032 (USD Million)
7. Global Cytomegalovirus Treatment Market, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.2.1. Global Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
7.3. Hospital Pharmacy
7.3.1. Global Cytomegalovirus Treatment Market, by Hospital Pharmacy, By Region, 2019-2032 (USD Million)
7.4. Retail Pharmacy
7.4.1. Global Cytomegalovirus Treatment Market, by Retail Pharmacy, By Region, 2019-2032 (USD Million)
7.5. Others
7.5.1. Global Cytomegalovirus Treatment Market, by Others, By Region, 2019-2032 (USD Million)
8. Global Cytomegalovirus Treatment Market, by Geography
8.1. Key findings
8.2. Introduction
8.2.1. Cytomegalovirus Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
8.3. Cytomegalovirus Treatment Market - North America
8.3.1. North America: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.3.2. North America: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.3.3. North America: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.3.4. Cytomegalovirus Treatment Market - U.S.
8.3.4.1. U.S.: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.3.4.2. U.S.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.3.4.3. U.S.: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.3.5. Cytomegalovirus Treatment Market - Canada
8.3.5.1. Canada: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.3.5.2. Canada.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.3.5.3. Canada: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.4. Cytomegalovirus Treatment Market - Europe
8.4.1. Europe: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.4.2. Europe.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.3. Europe: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.4.4. Cytomegalovirus Treatment Market - UK
8.4.4.1. UK: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.4.4.2. UK.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.4.3. UK: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.4.5. Cytomegalovirus Treatment Market - France
8.4.5.1. France: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.4.5.2. France.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.5.3. France: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.4.6. Cytomegalovirus Treatment Market - Germany
8.4.6.1. Germany: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.4.6.2. Germany.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.6.3. Germany: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.4.7. Cytomegalovirus Treatment Market - Italy
8.4.7.1. Italy: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.4.7.2. Italy.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.7.3. Italy: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.4.8. Cytomegalovirus Treatment Market - Spain
8.4.8.1. Spain: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.4.8.2. Spain.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.8.3. Spain: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.4.9. Cytomegalovirus Treatment Market - Netherlands
8.4.9.1. Netherlands: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.4.9.2. Netherlands.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.9.3. Netherlands: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.4.10. Cytomegalovirus Treatment Market - Russia
8.4.10.1. Russia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.4.10.2. Russia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.10.3. Russia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.5. Cytomegalovirus Treatment Market - Asia Pacific
8.5.1. Asia Pacific: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.5.2. Asia Pacific.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.3. Asia Pacific: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.5.4. Cytomegalovirus Treatment Market - China
8.5.4.1. China: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.5.4.2. China.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.4.3. China: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.5.5. Cytomegalovirus Treatment Market - India
8.5.5.1. India: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.5.5.2. India.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.5.3. India: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.5.6. Cytomegalovirus Treatment Market - Malaysia
8.5.6.1. Malaysia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.5.6.2. Malaysia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.6.3. Malaysia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.5.7. Cytomegalovirus Treatment Market - Japan
8.5.7.1. Japan: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.5.7.2. Japan.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.7.3. Japan: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.5.8. Cytomegalovirus Treatment Market - Indonesia
8.5.8.1. Indonesia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.5.8.2. Indonesia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.8.3. Indonesia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.5.9. Cytomegalovirus Treatment Market - South Korea
8.5.9.1. South Korea: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.5.9.2. South Korea.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.9.3. South Korea: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.6. Cytomegalovirus Treatment Market - Middle East & Africa
8.6.1. Middle East & Africa: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.6.2. Middle East & Africa.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.6.3. Middle East & Africa: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.6.4. Cytomegalovirus Treatment Market - Saudi Arabia
8.6.4.1. Saudi Arabia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.6.4.2. Saudi Arabia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.6.4.3. Saudi Arabia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.6.5. Cytomegalovirus Treatment Market - UAE
8.6.5.1. UAE: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.6.5.2. UAE.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.6.5.3. UAE: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.6.6. Cytomegalovirus Treatment Market - Israel
8.6.6.1. Israel: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.6.6.2. Israel.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.6.6.3. Israel: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.6.7. Cytomegalovirus Treatment Market - South Africa
8.6.7.1. South Africa: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.6.7.2. South Africa.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.6.7.3. South Africa: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.7. Cytomegalovirus Treatment Market - Latin America
8.7.1. Latin America: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.7.2. Latin America.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.7.3. Latin America: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.7.4. Cytomegalovirus Treatment Market - Mexico
8.7.4.1. Mexico: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.7.4.2. Mexico.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.7.4.3. Mexico: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.7.5. Cytomegalovirus Treatment Market - Brazil
8.7.5.1. Brazil: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.7.5.2. Brazil.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.7.5.3. Brazil: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
8.7.6. Cytomegalovirus Treatment Market - Argentina
8.7.6.1. Argentina: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
8.7.6.2. Argentina.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
8.7.6.3. Argentina: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Bayer AG
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Bristol Myers Squibb
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Chimerix
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Clinigen Group
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. Eli Lilly and Company
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. F. Hoffmann-La Roche Ltd
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Fresenius Kabi
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Genentech, Inc.
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Gilead Sciences, Inc
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. GlaxoSmithKline plc
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
10.11. Merck & Co., Inc.
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Recent Development
10.12. Pfizer Inc
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Recent Development
10.13. Takeda Pharmaceuticals
10.13.1. Company Overview
10.13.2. Financial Performance
10.13.3. Product Benchmarking
10.13.4. Recent Development
10.14. Teva Pharmaceutical Industries Ltd.
10.14.1. Company Overview
10.14.2. Financial Performance
10.14.3. Product Benchmarking
10.14.4. Recent Development
10.15. Thermo Fisher Scientific
10.15.1. Company Overview
10.15.2. Financial Performance
10.15.3. Product Benchmarking
10.15.4. Recent Development